Who bought Pharmacyclics?
AbbVie
AbbVie will acquire all of the outstanding shares of common stock of Pharmacyclics through a tender offer, followed by a second-step merger. In the tender offer, AbbVie will offer to acquire all of the outstanding shares of Pharmacyclics’ common stock for $261.25 per share, consisting of cash and AbbVie common stock.
What pharmaceutical company makes Imbruvica?
IMBRUVICA® is a once-daily, first-in-class Bruton’s tyrosine kinase (BTK) inhibitor that is administered orally, and is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.
Where is Imbruvica manufacturer?
The Pharmacyclics name was retained, and it operates as a subsidiary of AbbVie from its previous Sunnyvale, California, headquarters. Janssen markets Imbruvica in Europe, the Middle East and Africa and AbbVie markets it in the United States.
Is pharmacyclics part of AbbVie?
About AbbVie Together with its wholly-owned subsidiary, Pharmacyclics , AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.
When did AbbVie acquire Pharmacyclics?
March 2015
Acquisition by AbbVie In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity.
Is there a generic brand for Imbruvica?
No. There is currently no therapeutically equivalent version of Imbruvica available in the United States. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imbruvica. These medications may be counterfeit and potentially unsafe.
How long has Imbruvica been on the market?
Since its launch in 2013, IMBRUVICA has received 11 FDA approvals across six disease areas: chronic lymphocytic leukemia (CLL) with or without 17p deletion (del17p); small lymphocytic lymphoma (SLL) with or without del17p; Waldenström’s macroglobulinemia (WM); previously-treated patients with mantle cell lymphoma (MCL …
Is pharmacyclics owned by AbbVie?
NORTH CHICAGO, Ill. , May 26, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie’s scientific and commercial presence in oncology.
Why did AbbVie buy Pharmacyclics?
Pharmacyclics commanded a rich price largely because of its potential blockbuster cancer drug, Imbruvica. Owning this treatment could reduce AbbVie’s dependence on its own star performer, rheumatoid arthritis drug Humira, which is facing patent expiration.
Is Imbruvica chemo?
Ibrutinib is not a chemotherapy drug but one of what are termed “targeted therapies.” Targeted therapy is the result of years of research dedicated to understanding the differences between cancer cells and normal cells.
Who owns AbbVie?
Pharmaceutical company AbbVie, spun off by Abbott Laboratories in 2012, is now larger than its erstwhile parent. AbbVie has a market cap of over $285 billion.
Who owns Humira?
AbbVie sells Humira today because its former parent company, Abbott Laboratories, in 2000 acquired Knoll Pharmaceuticals, the drugmaking business of German chemicals company BASF. At the time, Humira was called D2E7 and analysts believed it might someday make between $500 million to $1 billion annually.
Can you drink coffee with Imbruvica?
Drink fluids such as water, decaffeinated tea, and clear broth. Eat small meals often, and avoid very hot or spicy foods. Avoid greasy foods, bran, raw fruits and vegetables, and caffeine. Avoid alcohol and drinks with caffeine.
What is the phone number for Imbruvica?
Phone: 1-877-877-3536. Monday through Friday, 8AM to 8PM ET. For medical information inquiries. For medical information inquiries about IMBRUVICA® or to report a possible adverse event or product quality complaint, please contact Pharmacyclics Medical Information by using one of the following two methods:
When should Imbruvica be discontinued?
When a patient no longer requires therapy for the treatment of cGVHD, IMBRUVICA should be discontinued considering the medical assessment of the individual patient. Administration Administer IMBRUVICA at approximately the same time each day with a glass of water. Swallow tablets or capsule whole.
Can Imbruvica cause fetal harm when administered during pregnancy?
Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. Administration of ibrutinib to pregnant rats and rabbits during the period of organogenesis caused embryo- fetal toxicity including malformations at exposures that were 2-20 times higher than those reported in patients with hematologic malignancies.
What are the other malignancies associated with Imbruvica?
Other malignancies (10%), including non-skin carcinomas (4%), occurred among the 1,476 patients who received IMBRUVICA in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%). 5.7 Tumor Lysis Syndrome